NCT07900555CompletedPhase 2
Hypofractionated Radiotherapy With Magnetic Resonance Imaging-Guided Focal Boost and Pelvic Irradiation in High-Risk Prostate Cancer
Dose-Escalated Image-Guided Radiotherapy (IGRT) With Magnetic Resonance Imaging (MRI)-Based Target Definition for Locally and Regionally Advanced Prostate Cancer: A Phase II Study
Source: ClinicalTrials.gov · Last updated 30 Oct 2026
Brief summary (registry, in English)
This study evaluated long-term disease control and side effects of a moderately hypofractionated radiotherapy protocol for men with high-risk prostate cancer. The protocol combined three strategies in one course of 25 treatments: a higher dose (focal boost) to the tumor seen on magnetic resonance imaging (MRI), a reduced dose to the uninvolved parts of the prostate, and elective irradiation of the pelvic lymph nodes, together with hormone therapy. Patients were included at Haukeland University Hospital, Bergen, Norway, from 2014 to 2017, with outcomes evaluated up to 10 years after treatment.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 191 (actual)
- First submitted
- 21 Oct 2026
- Start date
- 24 Feb 2014
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Prostate cancer, Childhood cancers
- NCT number
- NCT07900555
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 191
- From 24 Feb 2014 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous pelvic radiotherapy
Other illness
- Inflammatory bowel disease, pronounced irritable bowel syndrome, or other severe comorbidity contraindicating local radiotherapy
Other
- Distant metastases
- Lymph node metastases cranial to the level of the fifth lumbar vertebra (L5)
- Hemochromatosis
Who the study is looking for
- Morphologically confirmed prostate cancer
- TNM stage T3-T4, N0-1, M0 tumors, or lower T stage with an estimated risk of lymph node metastases above 15% according to the Memorial Sloan Kettering Cancer Center nomogram
- Life expectancy of more than 5 years
- Adequate cognitive function
- Written informed consent
Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.